BANK OF MONTREAL /CAN/ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$913,000
-17.8%
359,381
-5.2%
0.00%
-100.0%
Q2 2021$1,111,000
+58.5%
379,081
+36.9%
0.00%
Q1 2021$701,000
+8662.5%
276,988
+6774.9%
0.00%
Q4 2020$8,000
+100.0%
4,0290.0%0.00%
Q3 2020$4,000
+33.3%
4,0290.0%0.00%
Q2 2020$3,0000.0%4,0290.0%0.00%
Q1 2020$3,000
-81.2%
4,029
-77.3%
0.00%
Q4 2019$16,000
+23.1%
17,734
+30.8%
0.00%
Q3 2019$13,00013,5590.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders